We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna (CI) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
Cigna (CI - Free Report) ended the recent trading session at $296.71, demonstrating a -1.74% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.46%. On the other hand, the Dow registered a gain of 0.48%, and the technology-centric Nasdaq increased by 0.7%.
The the stock of health insurer has risen by 2.67% in the past month, lagging the Medical sector's gain of 4.8% and the S&P 500's gain of 4.85%.
The investment community will be paying close attention to the earnings performance of Cigna in its upcoming release. It is anticipated that the company will report an EPS of $6.52, marking a 31.45% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $48.82 billion, up 6.72% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $24.82 per share and revenue of $192.81 billion, which would represent changes of +6.66% and +6.74%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Cigna. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% lower. Cigna is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Cigna's current valuation metrics, including its Forward P/E ratio of 12.17. This represents a discount compared to its industry's average Forward P/E of 16.85.
We can additionally observe that CI currently boasts a PEG ratio of 1.09. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - HMOs industry was having an average PEG ratio of 1.15.
The Medical - HMOs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 62, finds itself in the top 25% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cigna (CI) Stock Falls Amid Market Uptick: What Investors Need to Know
Cigna (CI - Free Report) ended the recent trading session at $296.71, demonstrating a -1.74% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.46%. On the other hand, the Dow registered a gain of 0.48%, and the technology-centric Nasdaq increased by 0.7%.
The the stock of health insurer has risen by 2.67% in the past month, lagging the Medical sector's gain of 4.8% and the S&P 500's gain of 4.85%.
The investment community will be paying close attention to the earnings performance of Cigna in its upcoming release. It is anticipated that the company will report an EPS of $6.52, marking a 31.45% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $48.82 billion, up 6.72% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $24.82 per share and revenue of $192.81 billion, which would represent changes of +6.66% and +6.74%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Cigna. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% lower. Cigna is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Cigna's current valuation metrics, including its Forward P/E ratio of 12.17. This represents a discount compared to its industry's average Forward P/E of 16.85.
We can additionally observe that CI currently boasts a PEG ratio of 1.09. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - HMOs industry was having an average PEG ratio of 1.15.
The Medical - HMOs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 62, finds itself in the top 25% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.